GLP-1 Drugs and HIV-Associated Lipohypertrophy: The Randomized Evidence

HIV-associated lipohypertrophy, the visceral fat that accumulates around the abdomen in people on long-term antiretroviral therapy, has spent two decades being described as difficult to treat. There is now a randomized, double-blind, placebo-controlled trial. Over 32 weeks, once-weekly semaglutide reduced abdominal visceral adipose tissue by about 30.6% against placebo, with total body fat down about 18.9%.^[1] It is a phase 2b trial at one site, and its own authors ask for larger ones before anybody calls this settled.

What the trial did

One hundred and eight adults with controlled HIV-1, a BMI of 25 or above and lipohypertrophy, none of them diabetic, were randomly assigned to semaglutide or placebo. The drug arm titrated over eight weeks and then held 1.0 mg weekly for twenty-four. Participants and staff all stayed masked. The primary outcome was not weight but where the fat was: adipose tissue quantity by body compartment.^[1]

Choosing compartments rather than the scale matters here. Visceral fat is the depot that carries the cardiometabolic risk in this condition, and in percentage terms it is the one that moved most. Where fat sits matters in the opposite condition too: in inherited lipodystrophy, where fat tissue is missing, the lipid with nowhere to go ends up in the liver and muscle.

What it cost in muscle, and whether that mattered

A separate single-arm study in people with HIV and fatty liver disease (MASLD) asked what the tissue loss consists of. Forty-six participants on semaglutide for twenty-four weeks had psoas muscle measured on MRI. Psoas volume fell 9.3% (95% CI −13.4 to −5.2). Muscle fat fraction did not meaningfully change.^[2]

Then it measured function, which is the part usually missing. A ten-time chair rise test improved by 1.27 seconds and gait speed by 0.05 m/s; neither reached significance. But the share of participants with slow gait speed (under 1 m/s) fell from 63% to 46%.^[2] So a real loss of muscle volume arrived without a measurable loss of what the muscle does.

Psoas volume fell 9.3%, and the share of participants with slow gait speed fell from 63% to 46%.

That is a twenty-four week window in fewer than fifty people, so it is not a guarantee for a longer course. Our page on what the body-composition studies measured sets out how rarely function is measured at all, and the protein and lab-panel guide covers the intake side.

What this does not tell you

• No GLP-1 is approved for HIV-associated lipohypertrophy. This is phase 2b evidence at a single US site.
• Everyone in the trial had controlled HIV-1 and none had diabetes, so it says nothing about people outside those criteria.
• It ran 32 weeks. Fat compartments and muscle over a longer course were not measured.
• Interactions with specific antiretroviral regimens were not the question the trial asked, and this article does not answer it either. Fat at the back of the neck was not measured; what is known about it is set out in buffalo hump and weight loss.
• Anything touching your antiretroviral therapy is a conversation with your HIV clinician, not something to change on the strength of a trial summary.